- Title
- Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder
- Creator
- Bangs, Mark E.; Hazell, Philip; Danckaerts, Marina; Hoare, Peter; Coghill, David R.; Wehmeier, Peter M.; Williams, David W.; Moore, Rodney J.; Levine, Louise
- Relation
- Pediatrics Vol. 121, Issue 2, p. E314-E320
- Publisher Link
- http://dx.doi.org/10.1542/peds.2006-1880
- Publisher
- American Academy of Pediatrics
- Resource Type
- journal article
- Date
- 2008
- Description
- Methods: Patients were aged 6 to 12 years and met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnostic criteria for attention-deficit/hyperactivity disorder with a Swanson, Nolan, and Pelham Rating Scale-Revised attention-deficit/hyperactivity disorder subscale score above age and gender norms; Clinical Global Impressions-Severity Scale score of ≥4; and Swanson, Nolan, and Pelham Rating Scale-Revised oppositional defiant disorder subscale score of ≥15. Patients were randomly assigned in a 2:1 ratio to receive 1.2 mg/kg per day of atomoxetine (n = 156) or placebo (n = 70) for 8 weeks. Treatment effect on oppositional defiant disorder and attention-deficit/hyperactivity disorder symptoms was measured by using the investigator-rated Swanson, Nolan, and Pelham Rating Scale-Revised. Results: Repeated-measures analysis demonstrated a statistically significant difference favoring atomoxetine over placebo in the reduction of Swanson, Nolan, and Pelham Rating Scale-Revised oppositional defiant disorder total scores. There were significant pairwise treatment differences at weeks 2 and 5 but not at week 8 postbaseline. A last-observation-carried-forward analysis showed Swanson, Nolan, and Pelham Rating Scale-Revised scores at endpoint for the atomoxetine and placebo groups were significantly different for attention-deficit/hyperactivity disorder symptoms but not for oppositional defiant disorder symptoms. Atomoxetine was superior to placebo in a last-observation-carried-forward analysis of Clinical Global Impression-Improvement and Clinical Global Impression-Severity scores. Conclusions: This study confirms previous findings that patients with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder show statistically and clinically significant improvement in attention-deficit/hyperactivity disorder symptoms and global clinical functioning when treated with atomoxetine. It remains uncertain, however, whether atomoxetine exerts a specific and enduring effect on oppositional defiant disorder symptoms.
- Subject
- ADHD; adolescents; atomoxetine
- Identifier
- uon:5283
- Identifier
- http://hdl.handle.net/1959.13/43156
- Identifier
- ISSN:0031-4005
- Reviewed
- Hits: 7108
- Visitors: 7380
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|